<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04782557</url>
  </required_header>
  <id_info>
    <org_study_id>2020.321</org_study_id>
    <nct_id>NCT04782557</nct_id>
  </id_info>
  <brief_title>EUS Guided HVA and PVA for Circulating Tumor DNA in Patients</brief_title>
  <official_title>Endoscopic Ultrasound Guided Hepatic and Portal Vein Aspiration for Circulating Tumor DNA in Patients Suffering From GI Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The discovery of cell-free circulating tumor DNA (crDNA) in blood and the maturation of&#xD;
      technologies for ctDNA analysis have presented an attractive opportunity for minimally&#xD;
      invasive &quot;liquid biopsy&quot; genomic diagnostics. The investigators plan to perform EUS-guided&#xD;
      portal vein and hepatic vein aspiration in GI cancers patients. The aim of the current study&#xD;
      is thus to examine the concentration of ctDNA in portal vein (EUS-guided PVA), hepatic vein&#xD;
      (EUS-guided HVA) and peripheral blood to understand the first pass effect of the liver with&#xD;
      gastrointestinal (GI) cancers, and the possibility of using ctDNA as a marker for&#xD;
      preoperative staging, restaging after neoadjuvant chemotherapy, and monitoring for&#xD;
      recurrence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The discovery of cell-free circulating tumor DNA (crDNA) in blood and the maturation of&#xD;
      technologies for ctDNA analysis have presented an attractive opportunity for minimally&#xD;
      invasive &quot;liquid biopsy&quot; genomic diagnostics. The investigators plan to perform EUS-guided&#xD;
      portal vein and hepatic vein aspiration in GI cancers patients. The aim of the current study&#xD;
      is thus to examine the concentration of ctDNA in portal vein (EUS-guided PVA), hepatic vein&#xD;
      (EUS-guided HVA) and peripheral blood to understand the first pass effect of the liver with&#xD;
      gastrointestinal (GI) cancers, and the possibility of using ctDNA as a marker for&#xD;
      preoperative staging, restaging after neoadjuvant chemotherapy, and monitoring for&#xD;
      recurrence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variant allelic fraction (expressed in %) of serum ctDNA from HVB, PVB and peripheral blood</measure>
    <time_frame>3 months</time_frame>
    <description>Plasma DNA will be extracted using the QIAamp Circulating Nucleic Acid Kit (Qiagen), and the concentration of the circulating tumor DNA will be reported in variant allelic fraction (expressed in %)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variant allelic fraction (expressed in %) of Genomic and proteomic analysis of ctDNA</measure>
    <time_frame>3 months</time_frame>
    <description>If ctDNA is identified, further genomic and proteomic analysis will be performed. It will be measured in terms variant allelic fraction (expressed in %)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Staging of the GI cancer</measure>
    <time_frame>3 months</time_frame>
    <description>The pathological TNM staging of the resected specimen will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>any recurrence of the tumor will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>overall survival will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>progression free survival will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success rate of EUS-PVA and HVA</measure>
    <time_frame>1 day</time_frame>
    <description>The technical success rate of the EUS guided procedure will be recorded. Reasons for failure of the cases will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events of EUS-PVA and HVA</measure>
    <time_frame>30 days</time_frame>
    <description>the adverse events of the EUS procedure will be recorded</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Circulating Tumor Cell</condition>
  <condition>Gastrointestinal Cancer</condition>
  <arm_group>
    <arm_group_label>EUS-guided PVA and HVA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will undergo EUS-guided PVA and HVA</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>EUS-guided portal vein and hepatic vein aspiration</intervention_name>
    <description>EUS-guided portal vein and hepatic vein aspiration</description>
    <arm_group_label>EUS-guided PVA and HVA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Age &gt;= 18 years old&#xD;
&#xD;
          2. Newly diagnosed stage II-IV distal gastric cancer, pancreatic cancer or colorectal&#xD;
             cancer&#xD;
&#xD;
          3. Undergoing treatment with either:&#xD;
&#xD;
               1. Surgery&#xD;
&#xD;
               2. Neoadjuvant chemotherapy&#xD;
&#xD;
               3. Neoadjuvant chemoirradiation&#xD;
&#xD;
               4. Palliative chemotherapy/ immunotherapy&#xD;
&#xD;
                  Exclusion criteria:&#xD;
&#xD;
               1. Synchronous cancer of other sites&#xD;
&#xD;
               2. Cardia, high lesser curve tumors, oesophagogastric junction tumors&#xD;
&#xD;
               3. Presence of bulky lymph nodes at lesser curve/ coeliac region precluding a clear&#xD;
                  EUS puncture site to portal vein and hepatic vein&#xD;
&#xD;
               4. Patients with coagulopathy (international normalized ratio &gt;1.3, partial&#xD;
                  thromboplastin time greater than twice that of control), platelet count&#xD;
                  &lt;50,000x103/uL&#xD;
&#xD;
               5. Patients unwilling to undergo follow-up assessments&#xD;
&#xD;
               6. Patients with liver cirrhosis, portal hypertension and/ or gastric varices&#xD;
&#xD;
               7. Patient refusal to participate&#xD;
&#xD;
                  -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shannon Chan, FRCSEd</last_name>
    <phone>852-35052627</phone>
    <email>shannonchan@surgery.cuhk.edu.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Chan, FRCSEd</last_name>
      <phone>852-35052627</phone>
      <email>shannonchan@surgery.cuhk.edu.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 5, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>CHAN SHANNON MELISSA</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>Circulating Tumor Cell</keyword>
  <keyword>Gastrointestinal Cancer</keyword>
  <keyword>Endoscopic ultrasound portal vein aspiration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

